| AXP |
Report |
EPS (Q2'26) |
BEAT |
pred ~$4.52 vs. cons $4.41 |
MEDIUM |
| AXP |
Report |
Total revenue net of interest (Q2'26) |
IN-LINE |
pred ~$19.8B vs. cons $19.7B |
MEDIUM |
| AXP |
Report |
Card Member billed business / spend growth YoY |
IN-LINE |
pred ~9% vs. cons ~9.5% (~1pt co-brand roll-off drag begins Q2) |
MEDIUM |
| AXP |
Guide |
FY2026 revenue growth guide |
UNCHANGED |
guide ~9-10% vs. cons ~9.7% (FY2026, reaffirmed not raised) |
MEDIUM |
| AXP |
Guide |
FY2026 EPS guide |
UNCHANGED |
guide ~$17.30-$17.90 vs. cons ~$17.70 (FY2026; upside reinvested, not raised) |
MEDIUM |
| AXP |
Guide |
Net card fee growth trajectory |
BETTER |
guide ~high-teens by year-end vs. cons ~+16% (FY2026 exit rate) |
MEDIUM |
| AXP |
Guide |
Credit / net write-off rate (US Consumer) |
UNCHANGED |
guide ~1.8% Q2 write-off vs. cons ~1.8% (generally stable 2026; June aided by asset sale) |
MEDIUM |
| AXP |
Return |
Day-1 residual (stock − beta × S&P 500) |
-1.5% |
— |
MEDIUM |
| AXP |
Return |
5-day cumulative residual |
-2.5% (FOLLOW-THROUGH) |
Likely EPS beat but reaffirmed (not raised) FY guide plus the newly-begun Amazon/Lowe's co-brand roll-off (~1pt billings drag) and asset-sale-flattered June write-offs give analysts reason to trim out-period billings/organic-growth estimates even after a headline beat. Stock already faded ~6% from its mid-July $361 high into the print, signaling de-risking; a 'reinvest-over-raise' posture at rich valuation caps upside, so the initial soft reaction follows through modestly lower as revisions net down. |
LOW |